Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial

Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial

Randomized double-blind placebo-controlled trials (RCTs) are regarded as the gold standard for clinical trials. While there are established standards to avoid unblinding, in RCTs using tetrahydrocannabinol (THC) containing cannabinoids, however, accidental unblinding and intentional self-unbinding m...

Full description

Bibliographic Details
Main Authors: Kirsten R. Müller-Vahl, Ewgeni Jakubovski, Carolin Fremer, Martina Lenz-Ziegenbein, Anika Großhennig, Carolin Klages, Armin Koch, Martina Haas, Anna Pisarenko
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Neuroscience
Subjects:
blinding
clinical trials
THC
RCT
cannabinoids
unblinding
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2022.793703/full

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2022.793703/full

Similar Items